New once-daily pill could simplify Wilson's disease treatment
NCT ID NCT07465718
First seen Apr 01, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study tests a new once-daily version of trientine against the standard drug penicillamine for people newly diagnosed with Wilson's disease, a genetic condition that causes copper buildup. About 38 children (aged 8+) and adults will take one of the two treatments for 48 weeks to see which controls copper levels better and is safer. Participants will have regular blood and urine tests and answer questionnaires about their well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.